TRTC Stock 0.880   +0.030 +3.50% Updated: 03-03-2019

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
97
TRTC Stock 0.880   +0.030 +3.50% Updated: 03-03-2019 $TRTC
Last Trade: 3/1/2019 2:24:00 PM

Last 0.880   +0.030 +3.50%
Open 0.850
Previous Close 0.850
Day High / Low 1.010 / 0.830
Year High / Low 0.660 / 0.058
Volume 3,373,575
Projected Volume 3373575 (265%)
# of Trades / Projected 1,685 / 1,685
Dividend / Yield - / 0.00%
Abnormal Activity NONE
Abnormal Volume ABNORMAL VOLUME
Gap NONE
Candle BULLISH
Volatility Today HIGH
Volatility Yesterday HIGH
Price Relativity
From 40 Day High 86%
From 80 Day High 48%
From 150 Day High 37%
From 40 Day Low 151%
From 80 Day Low 158%
From 150 Day Low 158%
Pivot Analysis
Price Pivot $ 0.910
Day Resistance 1 $ 0.990
Day Support 1 $ 0.800
Day Resistance 2 $ 1.090
Day Support 2 $ 0.720
Consolidations
Short Term NO
Medium Term NO
Long Term YES
Volume Indicators
20 Day Avg Vol 1,275,254
Today / 20 Day Avg Vol ABOVE
150 Day Avg Vol 1,115,451
Today / 150 Day Avg Vol ABOVE
Abnormal Volume ABNORMAL VOLUME
William Volume Accumulation bullish
Volume Price Trend bullish
Momentum Indicators
10 Day Trend bullish
40 Day Trend bearish
100 Day Trend bearish
Stochastics bearish
RSI neutral
MACD bearish
Moving Average Indictors
15 Day Trend bullish
45 Day Trend bullish
100 Day Trend bearish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? NONE
Volatility Index Today HIGH
Volatility Index Yesterday HIGH
10 Day Volatility INCREASING
20 Day Volatility INCREASING
40 Day Volatility DECREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Huawei Introduces Innovative Wearables for Enhanced Connectivity

Updated Category News Views 293

Huawei Unveils Next-Generation Wearables and Tablets At a much-anticipated event, Huawei Consumer Business Group (CBG) revealed a thrilling array of new products. This launch showcased a strong emphasis on trendy wearables and sophisticated tablets, highlighting the brand's dedication to innovation and a user-friendly design. Chic Wearables for Style and Utility Among the...

Continue Reading
Investigating Barnes & Noble Education: Shareholder Rights Explained

Updated Category News Views 155

Understanding the Investigation of Barnes & Noble Education In a proactive move for investors, the law firm Bragar Eagel & Squire, P.C. is currently investigating Barnes & Noble Education, Inc. (BNED). This investigation aims to determine whether the company potentially breached federal securities laws or engaged in unlawful business practices that could lead to...

Continue Reading
Bailey Kennedy Achieves Landmark Legal Win for Talisman Group

Updated Category News Views 171

Bailey Kennedy Achieves Legal Victory for Talisman Group Judge Rules LNW Violated Talisman's Distribution Agreement by Marketing Competing Game In a significant legal development, Bailey Kennedy, LLP has successfully represented The Talisman Group, LLC, the innovative minds behind EZ Baccarat. The firm has recently triumphed in a legal dispute against LNW Gaming, Inc.,...

Continue Reading
Join the Class Action Lawsuit Against Ardelyx, Inc. Now

Updated Category News Views 49

Join the Class Action Lawsuit Against Ardelyx, Inc. Attention Ardelyx, Inc. investors! There's an important class action lawsuit underway, and this is your opportunity to get involved. Bronstein, Gewirtz & Grossman, LLC, a respected law firm known for its dedication to investor advocacy, has announced a class action case involving Ardelyx, Inc. (NASDAQ: ARDX) and certain...

Continue Reading
Aileron Therapeutics Unveils Q3 2024 Financial Performance

Updated Category News Views 97

Aileron Therapeutics Reports Impressive Q3 2024 Financial Results Aileron Therapeutics, Inc. (NASDAQ: ALRN), a biopharmaceutical company committed to developing innovative medicines for orphan pulmonary diseases, has recently showcased significant progress with their third-quarter financial results. This quarter has been marked by promising advancements in clinical trials...

Continue Reading